Evaluation of the non-invasive indicators in predicting detrusor underactivity in individuals with small-volume prostatic hyperplasia and lower urinary tract symptoms

This study was aimed to retrospectively analyze the potential of non-invasive serum biomarkers in clinically predicting the detrusor underactivity (DU) in benign prostatic hyperplasia (BPH) patients with lower urinary tract symptoms (LUTS) and low prostate volume (PV). The study enrolled 196 patients with BPH and LUTS at our hospital in the period from January 2018 to October 2023. The patients were divided into two groups based on the projected isovolumetric pressure (PIP): the DU and the control groups. The patients included in the study had PV of less than 50 mL. A total of 93 and 103 cases were placed in the DU and control groups, respectively. Univariate analysis exhibited that the age was associated with DU occurrence (p = 0.004), and the serum prostate specific antigen (PSA) might act as DU protective factor (p = 0.001). However, there was no statistically significant relation between pre-selected serum hematological parameters and the DU diagnosis accuracy. Multivariate analysis suggested that only the age (OR (odds ratio) 1.07, 95% CI (confidence interval) 1.03–1.12, p = 0.001) and PSA (OR 0.79, 95% CI 0.69–0.90, p < 0.001) were the independent predictors of DU. In this study, it was observed that the pre-selected serum hematological parameters had no relevance in diagnosing DU in low PV male patients. Nonetheless, it was found that the age and PSA could be the independent non-invasive predictors of male patients with LUTS and low PV, who were unable to undergo urodynamic examinations.

Prostatic hyperplasia; Lower urinary tract symptoms; Detrusor underactivity; Serum hematological parameters

[1] Gravas S, Malde S, Cornu JN, Gacci M, Gratzke C, Herrmann TRW, et al. From BPH to male LUTS: a 20-year journey of the EAU guidelines. To be published in Prostate Cancer and Prostatic Diseases. 2023. [Preprint].

[2] Huang J, Chan C, Yee S, Deng Y, Bai Y, Chan SC, et al. Global burden and temporal trends of lower urinary tract symptoms: a systematic review and meta-analysis. Prostate Cancer and Prostatic Diseases. 2023; 26: 421–428.

[3] Lee CL, Jhang JF, Ho HC, Jiang YH, Hsu YH, Kuo HC. Therapeutic outcome of active management in male patients with detrusor underactivity based on clinical diagnosis and videourodynamic classification. Scientific Reports. 2022; 12: 362.

[4] Bayrak Ö, Dmochowski RR. Underactive bladder: a review of the current treatment concepts. Turkish Journal of Urology. 2019; 45: 401–409.

[5] Kim DK. Current pharmacological and surgical treatment of underactive bladder. Investigative and Clinical Urology. 2017; 58: S90–S98.

[6] Luo F, Sun H, Su Y, Zhang Z, Wang Y, Zhao Z, et al. Assessment of noninvasive predictors of bladder detrusor underactivity in BPH/LUTs patients. International Urology and Nephrology. 2017; 49: 787–792.

[7] Kim M, Yu HY, Ju H, Shin JH, Kim A, Lee J, et al. Induction of detrusor underactivity by extensive vascular endothelial damages of iliac arteries in a rat model and its pathophysiology in the genetic levels. Scientific Reports. 2019; 9: 16328.

[8] Majolée J, Kovačević I, Hordijk PL. Ubiquitin-based modifications in endothelial cell-cell contact and inflammation. Journal of Cell Science. 2019; 132: jcs227728.

[9] Yu YD, Jeong SJ. Epidemiology of underactive bladder: common but underresearched. Investigative and Clinical Urology. 2017; 58: S68–S74.

[10] Griffiths D. Detrusor contractility—order out of chaos. Scandinavian Journal of Urology and Nephrology. 2004; 38: 93–100.

[11] Jeong SJ, Kim HJ, Lee YJ, Lee JK, Lee BK, Choo YM, et al. Prevalence and clinical features of detrusor underactivity among elderly with lower urinary tract symptoms: a comparison between men and women. Korean Journal of Urology. 2012; 53: 342–348.

[12] Meng J, Liu Y, Guan S, Ma H, Zhang X, Fan S, et al. Age, height, BMI and FBG predict prostate volume in ageing benign prostatic hyperplasia: evidence from 5285 patients. To be published in International Journal of Clinical Practice. 2019. [Preprint].

[13] Wang SB, Chen JY, Xu C, Cao WG, Cai R, Cao L, et al. Evaluation of systemic inflammatory and nutritional indexes in locally advanced gastric cancer treated with adjuvant chemoradiotherapy after D2 dissection. Frontiers in Oncology. 2022; 12: 1040495.

[14] Fluss R, Faraggi D, Reiser B. Estimation of the Youden index and its associated cutoff point. Biometrical Journal. 2005; 47: 458–472.

[15] Osman NI, Esperto F, Chapple CR. Detrusor underactivity and the underactive bladder: a systematic review of preclinical and clinical studies. European Urology. 2018; 74: 633–643.

[16] Aldamanhori R, Chapple CR. Underactive bladder, detrusor underactivity, definition, symptoms, epidemiology, etiopathogenesis, and risk factors. Current Opinion in Urology. 2017; 27: 293–299.

[17] Ameda K, Sullivan MP, Bae RJ, Yalla SV. Urodynamic characterization of nonobstructive voiding dysfunction in symptomatic elderly men. The Journal of Urology. 1999; 162: 142–146.

[18] Kullmann FA, Birder LA, Andersson K. Translational research and functional changes in voiding function in older adults. Clinics in Geriatric Medicine. 2015; 31: 535–548.

[19] Kaynar M, Yıldırım ME, Badem H, Çaviş M, Tekinarslan E, İstanbulluoğlu MO, et al. Bladder cancer invasion predictability based on preoperative neutrophil-lymphocyte ratio. Tumor Biology. 2014; 35: 6601–6605.

[20] Xu X, Jing J. Inflammation-related parameter serve as prognostic biomarker in esophageal squamous cell carcinoma. Frontiers in Oncology. 2022; 12: 900305.

[21] Korkmaz M, Erylmaz MK. Systemic inflammatory markers predicting the overall survival of patients using tyrosine kinase inhibitors in the first-line treatment of metastatic renal cell carcinoma. Journal of the College of Physicians and Surgeons Pakistan. 2023; 33: 653–658.